Published Date: 06 Mar 2023
The Master Chirurgiae in Pediatric Orthopedics, also known as MCh Pediatric Orthopedics or MCh in Pediatric Orthopedics, is the highest degree...
Read Full NewsHistorical anatomical illustrations reflect social inequality and may require an ethical context to guide their continued use in clinical education and surgical reference.
New data highlight the activity and safety of MRD-guided preemptive azacitidine in patients with myelodysplastic neoplasms or AML who develop MRD positivity.
Researchers examine overall response rates of a HER3-targeting antibody-drug conjugate in pretreated patients with non-small cell lung cancer.
1.
'Chemo brain' cognitive issues linked to poor lymphatic-system drainage
2.
Chris Hoy reveals that he has terminal cancer?here's how to spot early signs of prostate cancer
3.
In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.
4.
Geriatric Assessment, QoL Correlate With OS in Older Patients with Pancreatic Cancer
5.
Upping Immunotherapy Activity; A Win for Lung Screening; Looming Drug Price Break?
1.
The Cutting-Edge of Phlebectomy: Redefining Vein Care
2.
Unlocking the Mystery of Granulomas: A Closer Look at the Causes and Treatment
3.
Everything You Need To Know About Trichelemmal Cysts: Symptoms, Causes, Diagnosis And Treatment
4.
Deciphering FFR: A Comprehensive Guide to Understanding Its Meaning
5.
Hepatocellular Carcinoma: Emerging Trends and Innovations in Diagnosis and Management
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
2.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
3.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
4.
L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients
5.
Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation